Bayer and Orion expand BAY-1841788 programme in prostate cancer
Bayer and Orion are expanding the development programme for the investigational androgen receptor (AR) antagonist BAY-1841788 (ODM-201) in the area of prostate cancer.
Click on this link for more information.
